Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the G8 Questionnaire and the Groningen Frailty Indicator to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

NCT05051956 is registered in ClinicalTrials.gov with Namik Kemal University as lead sponsor.

NCT NCT05051956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05051956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the G8 Questionnaire and the Groningen Frailty Indicator to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?
Lead sponsor
Namik Kemal University
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2021
Completion date
December 15, 2021
Enrollment
140 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

can the geriatric questionnaires predict adverse effects in geriatric breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors